Eli Lilly has expressed reservations about the Novo-Catalent deal and its potential impact on the wider manufacturing industry.
“Given the nature of this transaction — a vertical integration where the client list of Catalent might number in excess of 100 entities, all of which plan to compete in some way with Novo Nordisk — it sets up for an interesting inquiry by everybody [including] politicians,” CEO David Ricks said in an interview with the Financial Times.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.